Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
Clinical trial NCT05798156 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05798156
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-20
- Primary completion
- 2025-04-12
- Enrollment
- 125
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.